Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering Expression of IL-12
This is a phase 1 study (the first stage in testing a new treatment to see how safe and
tolerable the treatment is) which will include patients with acute myeloid leukemia (AML)
that has either returned or has a more than a 70% chance of coming back and cannot have a
bone marrow transplant.
This study will see whether modifying a patient's AML cells to produce IL-12 and giving it
back to the patient is safe and useful in patients with AML that cannot have bone marrow
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society